Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
grade F 18.67 -0.64% -0.12
CLLS closed down 0.64 percent on Friday, May 17, 2019, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CLLS trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
50 DMA Resistance Bearish -0.64%
Bearish Engulfing Bearish -0.64%
180 Bearish Setup Bearish Swing Setup -0.64%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.64%
Outside Day Range Expansion -0.64%
NR7 Range Contraction -2.10%
Lower Bollinger Band Walk Weakness -2.10%
Oversold Stochastic Weakness -2.10%
Stochastic Buy Signal Bullish -1.06%

Older signals for CLLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Multiple Myeloma Glioblastoma Leukemia Chronic Lymphocytic Leukemia Hematologic Malignancies Solid Tumor Oncogenes Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Cellectis
Is CLLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 31.57
52 Week Low 15.34
Average Volume 119,380
200-Day Moving Average 21.9984
50-Day Moving Average 19.2234
20-Day Moving Average 19.5205
10-Day Moving Average 19.115
Average True Range 0.6358
ADX 14.37
+DI 18.8709
-DI 19.8238
Chandelier Exit (Long, 3 ATRs ) 18.9326
Chandelier Exit (Short, 3 ATRs ) 19.8774
Upper Bollinger Band 20.7977
Lower Bollinger Band 18.2433
Percent B (%b) 0.17
BandWidth 13.08573
MACD Line -0.1761
MACD Signal Line -0.0231
MACD Histogram -0.153
Fundamentals Value
Market Cap 668.19 Million
Num Shares 35.8 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -8.12
Price-to-Sales 23.25
Price-to-Book 4.09
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.18
Resistance 3 (R3) 19.21 19.08 19.10
Resistance 2 (R2) 19.08 18.95 19.06 19.07
Resistance 1 (R1) 18.87 18.87 18.81 18.84 19.04
Pivot Point 18.74 18.74 18.70 18.72 18.74
Support 1 (S1) 18.53 18.61 18.47 18.50 18.30
Support 2 (S2) 18.40 18.53 18.38 18.27
Support 3 (S3) 18.19 18.40 18.25
Support 4 (S4) 18.16